Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ombrabulin plus taxane and platinum versus placebo plus taxane and platinum in first-line metastatic non-small cell lung cancer
2010-019384-11Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ombrabulin + taxane + platinum with Placebo + taxane + platinum (2 arms). Primary endpoint: Progression-free survival. Started Nov 2010; status: completed.
02
Drugs
Ombrabulin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-019384-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019384-11.